annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 13C Results of new cases of APL treatment by arsenic trioxide and long-term
follow-up: Is it time for using arsenic trioxide in first-line treatment?
(Abstract #6545)
A. Ghavamzadeh, K. Alimoghaddam, S. Ghaffari, S. Rostami, M. Jahani,
M. Iravani, S. Mousavi, M. Jalili, N. Alizadeh, A. Khodabandeh, Hematology,
Oncology and Stem Cell Transplantation Research Center of Tehran University of
Medical Sciences
Brd. 13D Use of deep whole transcriptome sequencing in Philadelphia-positive acute
lymphoblastic leukemia (ALL) to identify novel mutated genes and aberrant
gene expression and alternative splicing profiles associated with disease
progression. (Abstract #6546)
I. Iacobucci, A. Ferrarini, M. Sazzini, A. Lonetti, E. Giacomelli, L. Xumerle,
A. Ferrari, C. Papayannidis, M. Delledonne, G. Martinelli
Brd. 13E The relationship of cigarette smoking to invasive fungal disease (IFD) in
acute myeloid leukemia (AML) patients undergoing induction chemotherapy
(IC). (Abstract #6547)
M. G. Mansour, A. Z. Fu, E. A. Copelan, M. E. Kalaycio, A. S. Advani,
Y. Saunthararajah, R. M. Sobecks, M. A. Sekeres
Brd. 13F Dynamic of morphologic and molecular remission in patients (pts) with APL
treated with frontline ATRA and arsenic trioxide (ATO). (Abstract #6548)
M. Ayoubi, H. Kantarjian, J. E. Cortes, S. Faderl, G. Garcia-Manero, S. Wen,
J. Fiorentino, X. Huang, R. Luthra, F. Ravandi Kashani
Brd. 13G Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients
(pts) with advanced myeloid malignancies. (Abstract #6549)
A. Dean, M. Talpaz, H. Kantarjian, S. Faderl, E. Jabbour, F. Ravandi Kashani,
S. M. O’Brien, M. Rosenblum, J. E. Cortes
Brd. 13H Correlation of RASGRP1/APTX ratio with clinical response and survival in
AML patients treated with tipifarnib-bortezomib combination. (Abstract
#6550)
G. Martinelli, S. Paolini, C. Papayannidis, E. Ottaviani, S. Parisi, I. Iacobucci,
A. Curti, D. Cilloni, G. Saglio, A. Candoni, M. Baccarani
Brd. 14A Analysis of survival of older patients with frontline AML treated with
clofarabine with or without low-dose cytarabine or intermediate-dose
cytarabine: A matched cohort comparison. (Abstract #6551)
S. Faderl, F. Ravandi Kashani, G. Borthakur, T. M. Kadia, E. Jabbour, G. Garcia-
Manero, M. Brandt, S. Pierce, H. Kantarjian
Brd. 14B Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and
gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor
associated acute myelogenous leukemia (CBF-AML). (Abstract #6552)
G. Borthakur, E. Jabbour, X. Wang, J. E. Cortes, F. Ravandi Kashani, T. M. Kadia,
J. Bass, M. Brandt, H. Kantarjian
Brd. 14C Association of lymphocytosis following treatment with dasatinib with
response and outcome. (Abstract #6553)
C. A. Schiffer, J. E. Cortes, G. Saglio, P. le Coutre, E. Bahceci, D. Dejardin,
N. P. Shah
Brd. 14D Association between imatinib transporters and metabolizing enzymes
genotype and response in newly diagnosed chronic myeloid leukemia (CML)
patients. (Abstract #6554)
S. Soverini, S. Angelini, M. Barnett, M. Thornquist, E. Turrini, G. Rosti, P. Hrelia,
T. Kalebic, M. Baccarani, G. Martinelli
Brd. 14E Decitabine therapy in patients with AML or MDS and chromosome 5, 7, or 8
abnormalities. (Abstract #6555)
S. R. Mohan, M. A. Sekeres, Y. Saunthararajah, J. P. Maciejewski
93
SATURDAY